Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.38 |
| ▸ | NQO2 | P16083 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198116 | 0.91 | NR4A2 (0.41) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL23926132 | 0.91 | NR4A2 (0.41) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL30240629 | 0.82 | NR4A2 (0.44) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL23950893 | 0.82 | NR4A2 (0.44) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL23043368 | 0.78 | NR4A2 (0.40) | NR4A2NQO2KDM4E | |
| SCHEMBL29680567 | 0.78 | NR4A2 (0.40) | NR4A2NQO2KDM4E | |
| SCHEMBL30729539 | 0.75 | SLC6A3 (0.40) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL27179165 | 0.75 | SLC6A3 (0.40) | NR4A2PDK2NQO2TSHRHTT | |
| SCHEMBL23951167 | 0.75 | SOS1 (0.40) | PDK2GAAABL1CHRNA7MAPT | |
| SCHEMBL30729543 | 0.72 | SLC6A3 (0.44) | NR4A2PDK2NQO2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | NR4A2 2828/4885PDK2 1387/4885NQO2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.